A randomized controlled trial found 5-HTP did not improve distractibility or attention measures in adults with high ADHD traits, and caused adverse effects in nearly 20% of participants.
Researchers at PLoS One conducted a randomized, double-blind, placebo-controlled trial to test whether 5-HTP, a serotonin precursor, could reduce distractibility in adults displaying high levels of ADHD traits. The motivation behind the study was sound: current pharmaceutical treatments for ADHD carry substantial misuse risk and high discontinuation rates, prompting exploration of alternative approaches. The serotonin synthesis pathway has been hypothesized as a potential locus of dysfunction in ADHD, making serotonergic intervention a plausible direction to investigate.
The trial enrolled 112 adults stratified by ADHD symptom severity using the Adult ADHD Self-Report Scale screener (ASRS v1.1). Participants were divided into high-ADHD-traits (N=56) and low-ADHD-traits (N=56) groups, with randomized allocation to either 5-HTP or placebo in a 1:1 ratio. Baseline distractibility was measured using two tasks: an Eriksen flanker task (task-relevant distraction) and an N-back task paired with auditory stimuli (task-irrelevant distraction). Participants completed these tasks, received their assigned intervention, and repeated the tasks 90 minutes post-administration. This acute dosing approach allowed researchers to isolate the immediate biochemical effects of 5-HTP on attention processes.
The results were largely negative. 5-HTP produced no significant improvements in any measure of distractibility that distinguished individuals with high versus low ADHD traits. The flanker task and primary N-back measures showed no benefit. The only statistically significant finding worked against 5-HTP: on silent N-back trials, placebo participants improved performance while 5-HTP participants did not, suggesting a potential impairment relative to placebo. Additionally, 19.6% of participants in the 5-HTP group experienced adverse events including fatigue, nausea, or vomiting, compared to baseline expectations. The high-ADHD-traits group showed few performance differences from the low-ADHD-traits group on either task, limiting the ability to detect selective benefits within the symptomatic population.
The authors acknowledge a key limitation: the tasks used may not have been sufficiently sensitive to the specific attention deficits present in ADHD. The N-back task failed to produce the predicted distractor effect, and neither task substantially differentiated the high and low ADHD groups at baseline. This means the study may have been underpowered to detect benefits if they exist, or the specific measures chosen were not optimal for assessing ADHD-relevant attention domains. However, the absence of positive signal paired with adverse effects suggests 5-HTP is unlikely to be a straightforward treatment avenue for ADHD-related inattention.
This trial provides clear evidence that acute 5-HTP supplementation does not improve distractibility or attention in adults with high ADHD traits. If you are considering 5-HTP as a tool for attention or focus, this study does not support that use. The adverse effect rate of approximately 1 in 5 participants experiencing fatigue, nausea, or vomiting is also notable and should be weighed against any potential benefits.
The broader takeaway is that serotonergic intervention via serotonin precursors may not be a primary mechanism for addressing ADHD-related attention dysfunction, at least not through acute administration. The dopaminergic and noradrenergic systems remain the targets of established ADHD pharmacotherapy, and this result suggests those systems may be more central to ADHD pathophysiology than acute serotonin elevation.
If you have high ADHD traits and are exploring non-pharmacological or supplemental approaches, this study does not recommend 5-HTP. Established behavioral and cognitive interventions, lifestyle modifications like sleep duration, morning-exercise, deep-work scheduling, and evidence-based medical approaches remain the standard recommendations. Anyone using 5-HTP for any purpose should discuss it with a healthcare provider, as this study suggests potential adverse effects warrant monitoring.
| Parameter | Details |
|---|---|
| Study Type | Randomized controlled trial, double-blind |
| Sample | 112 adults (56 high ADHD traits, 56 low ADHD traits) |
| Intervention | Acute 5-HTP vs placebo |
| Primary Outcomes | Distractibility on flanker and N-back tasks |
| Key Finding | No significant improvement in distractibility; 19.6% adverse event rate |
| Evidence Tier | C (small RCT with null findings) |
| Journal | PLoS One |
| PubMed ID | 42160304 |
Zhai, J., et al. "The effect of 5-hydroxytryptophan, a serotonin precursor, on adults with high levels of Attention Deficit Hyperactivity Disorder traits: A randomised, controlled trial." PLoS One (2024). PubMed: 42160304
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.